Thailand Plans To Produce Own Generics Of Major Drugs
This article was originally published in PharmAsia News
Thailand's Government Pharmaceutical Organization is building a $22.2 million plant to manufacture its own versions of major drugs it feels are too expensive. The plant is expected to be completed within six months and able to produce its first drugs early next year, at a rate of three billion tablets a year. The GPO currently imports generics from other countries to replace branded drugs it has declared subject to compulsory license. With its own plant, the agency hopes to save money on even the imports and speed patient access to the medicines. (Click here for more
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.